Zacks: Galena Biopharma, Inc. (NYSE:SLS) Receives Consensus Rating of “Buy” from Brokerages

Galena Biopharma, Inc. (NYSE:SLS) has been given a consensus broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company.

Brokers have set a one year consensus target price of $8.75 for the company and are anticipating that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also assigned Galena Biopharma an industry rank of 51 out of 256 based on the ratings given to related companies.

Shares of Galena Biopharma stock traded up $0.02 during midday trading on Friday, hitting $0.16. The company had a trading volume of 100,612,125 shares, compared to its average volume of 8,773,012. The company’s 50 day moving average price is $0.19. Galena Biopharma has a 1-year low of $0.10 and a 1-year high of $2.46.

Galena Biopharma (NYSE:SLS) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.06.

About Galena Biopharma

Develop biopharmaceuticals

Featured Story: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Galena Biopharma (SLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.